PMV Pharmaceuticals, Inc.

Drug developers and investors left San Francisco after the recent J.P. Morgan Healthcare Conference feeling optimistic about prospects for returns on biopharmaceutical investments, certain that forthc

Initial public offerings in the US have been remarkable across industries, but the biopharmaceutical sector has dominated in terms of the number of IPOs and the performance of newly issued stocks in t

The question of where former Allergan plc CEO Brent Saunders would land next after the company was sold to AbbVie Inc. earlier this year for $63bn was answered in a 10 September filing with the US

Venture capital investment in biopharmaceutical companies is booming in 2020. And while novel cancer and immuno-oncology programs continue to attract large sums, drug developers working on treatments